NEW YORK, Jan 5, 2026, 13:54 EST — Regular session
- Structure Therapeutics shares fell 7.7% to $62.86, after trading as high as $72.02 earlier in the session.
- Selling rippled across oral obesity-drug names as Novo Nordisk began U.S. sales of a Wegovy pill aimed at cash-paying patients.
- Investors are watching for updates on Structure’s Phase 3 pathway and its next earnings report (estimated Feb. 26).
Structure Therapeutics shares fell 7.7% to $62.86 in afternoon trade on Monday, paring an earlier rally and marking another volatile session for the obesity-drug developer. The stock has ranged from $72.02 to $62.50 so far in the regular session.
The move came as Novo Nordisk began U.S. sales of a once-daily pill version of Wegovy, bringing a branded oral option into pharmacies at $149 a month for starter doses for self-paying patients, Reuters reported. Novo’s website shows higher-dose pricing at $299 a month, with the 4 mg dose set to rise to $199 from April 15.
That matters for Structure because the company is developing its own oral GLP-1 obesity pill, aleniglipron, a small-molecule drug designed to mimic the appetite-suppressing effects of the GLP-1 hormone. “The price was lower than expected,” said Matt Weston, a pharmaceutical analyst at UBS, referring to Novo’s launch. The Guardian
Novo’s U.S.-listed shares rose 4.5% on Monday, while Eli Lilly slid 3.8% and Viking Therapeutics fell 9.7%, highlighting how quickly pricing and access shifts can reprice companies tied to the oral obesity race.
Structure, a Nasdaq-listed clinical-stage biotech based in South San Francisco, is building a pipeline of oral small-molecule drugs for metabolic diseases and other conditions. Its most advanced candidate, aleniglipron, targets the GLP-1 receptor, a validated pathway for weight loss and diabetes.
In December, Structure said aleniglipron produced placebo-adjusted weight loss of 11.3% at 36 weeks at the 120-mg dose in its Phase 2b ACCESS study, with an exploratory study showing up to 15.3% at higher dosing. The company said it plans to seek an FDA Type B end-of-Phase 2 meeting in the first half of 2026 — a sit-down with regulators to agree the design of Phase 3 trials, the final stage of testing before a potential approval — and aims to begin Phase 3 by mid-2026.
Structure also tapped equity markets after the trial update, closing an upsized $747.5 million public offering priced at $65 per American depositary share, the company said. An ADS is a U.S.-traded certificate that represents shares in a foreign company.
Shares more than doubled on Dec. 8 after Structure released its mid-stage obesity data, a jump that underscored both enthusiasm — and sensitivity — around a market that analysts estimate could be worth about $150 billion annually by the early 2030s.
Still, Monday’s drop underlines a central risk for bulls: Novo’s pill brings an oral alternative to market now, and aggressive cash pricing could tighten the commercial window for experimental pills still in development. Structure must also prove its efficacy and safety hold up in larger, longer Phase 3 studies.
